Comparative effectiveness research: What is it and why do we need it in nephrology?

Nephrology Dialysis Transplantation

Volumn 27, Issue 6, 2012, Pages 2156-2161

  Chang, Tara I ^a   Winkelmayer, Wolfgang C ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Comparative effectiveness; Epidemiology; Methods; Outcomes; Review

Indexed keywords

CHRONIC KIDNEY DISEASE; COMPARATIVE EFFECTIVENESS; CONFOUNDING VARIABLE; GLOMERULUS FILTRATION RATE; KIDNEY FAILURE; META ANALYSIS (TOPIC); NEPHROLOGY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROPENSITY SCORE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL REPLACEMENT THERAPY; REVIEW; SYSTEMATIC REVIEW (TOPIC);

COMPARATIVE EFFECTIVENESS RESEARCH; DELIVERY OF HEALTH CARE; EVIDENCE-BASED MEDICINE; HUMANS; NEPHROLOGY; UNITED STATES;

EID: 84861912169     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfs154     Document Type: Review

References (55)

1. Organisation for Economic Co-operation and Development (OECD). OECD Health Data 2011-Frequently Requested Data. 2011; http://www.oecd.org/document/ 16/0, 3746, en-2649-37407-2085200-1-1-1-37407,00.html (19 March 2012, date last accessed)
2. McCarthy D, How SKH, Schoen C et al. Aiming Higher Results from a State Scorecard on Health System Performance. The Commonwealth Fund, 2009
3. Centers for Medicare and Medicaid Services. National Health Expenditure Data. 2012: https://www.cms.gov/NationalHealthExpendData/(22 March 2012, date last accessed)
4. American Recovery and Reinvestment Act of 2009 Challenge Grant Applications: Omnibus of Broad Challenge Areas and Specific Topics. Bethesda, MD: National Institutes of Health, 2009
5. Washington AE, Lipstein SH. The Patient-centered outcomes research institute-promoting better information, decisions, and health. N Engl J Med 2011; 365: e31
6. Federal Coordinating Council for Comparative Effectiveness Research. Report to the President and the Congress. US Department of Health and Human Services, 2009; http://www.hhs.gov/recovery/programs/cer/cerannualrpt.pdf.
7. Institute of Medicine. Initial National Priorities for Comparative Effectiveness Research. Washington, DC: Institute of Medicine of the National Academies, 2009; http://www.iom.edu/Reports/2009/ ComparativeEffectivenessResearchPriorities.aspx (19March 2012, date last accessed)
8. Thorpe KE, Zwarenstein M, Oxman AD et al. A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers. J Clin Epidemiol 2009; 62: 464-475
9. Coca SG, Krumholz HM, Garg AX et al. Underrepresentation of renal disease in randomized controlled trials of cardiovascular disease. JAMA 2006; 296: 1377-1384
10. Gartlehner G, Hansen RA, Nissman D et al. A simple and valid tool distinguished efficacy from effectiveness studies. J Clin Epidemiol 2006; 59: 1040-1048
11. Elley CR, Chondros P, Kerse NM. Randomised trials-cluster versus individual randomisation. Primary Care Alliance for Clinical Trials (PACT) network. Aust fam physician 2004; 33: 759-763
12. Manns B, Tonelli M, Culleton B et al. A cluster randomized trial of an enhanced eGFR prompt in chronic kidney disease. Clin J Am Soc Nephrol 2012; 7: 565-572
13. Orth SR, Hallan SI. Smoking: a risk factor for progression of chronic kidney disease and for cardiovascular morbidity and mortality in renal patients-absence of evidence or evidence of absence? Clin J Am Soc Nephrol 2008; 3: 226-236
14. Manns B, Owen WF Jr, Winkelmayer WC et al. Surrogate markers in clinical studies: problems solved or created? Am J Kidney Dis 2006; 48: 159-166
15. Winkelmayer WC, Setoguchi S, Levin R et al. Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy. Arch Intern Med 2008; 168: 2368-2375
16. Juurlink DN, Gomes T, Lipscombe LL et al. Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study. BMJ 2009; 339: b2942
17. Graham DJ, Ouellet-Hellstrom R, MaCurdy TE et al. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA 2010; 304: 411-418
18. Moher D, Hopewell S, Schulz KF et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. J Clin Epidemiol 2010; 63: e1-e37
19. Jadad AR, Moore RA, Carroll D et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12
20. Pfeffer MA, Burdmann EA, Chen C-Y et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361: 2019-2032
21. Reddan DN, Szczech LA, Hasselblad V et al. Intradialytic blood volume monitoring in ambulatory hemodialysis patients: a randomized trial. J Am Soc Nephrol 2005; 16: 2162-2169
22. Sharif A, Shabir S, Chand S et al. Meta-analysis of calcineurininhibitor- sparing regimens in kidney transplantation. J Am Soc Nephrol 2011; 22: 2107-2118
23. Sandhu S, Wiebe N, Fried LF et al. Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol 2006; 17: 2006-2016
24. von Elm E, Altman DG, EggerMet al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007; 370: 1453-1457
25. Molnar AO, Coca SG, Devereaux PJ et al. Statin use associates with a lower incidence of acute kidney injury after major elective surgery. J Am Soc Nephrol 2011; 22: 939-946
26. Tentori F, Zhang J, Li Y et al. Longer dialysis session length is associated with better intermediate outcomes and survival among patients on in-center three times per week hemodialysis: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2012
27. Dreyer NA, Schneeweiss S, McNeil BJ et al. GRACE principles: recognizing high-quality observational studies of comparative effectiveness. Am J Manag Care 2010; 16: 467-471
28. European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP). Guide on Methodological Standards in Pharmacoepidemiology. European Medicines Agency, 2012. http://www.encepp.eu/ standards-and-guidances/documents/ENCePPGuideofMethStandardsin-PE.pdf (21 March 2012, date last accessed)
29. Liberati A, Altman DG, Tetzlaff J et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 2009; 62: e1-e34
30. Moher D, Cook DJ, Eastwood S et al. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. The Lancet 1999; 354: 1896-1900
31. Maione A, Navaneethan SD, Graziano G et al. Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in patients with micro-and macroalbuminuria and other cardiovascular risk factors: a systematic review of randomized controlled trials. Nephrol Dial Transplant 2011; 26: 2827-2847
32. Higgins JPT, Green S.Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011], The Cochrane Collaboration. Available from www.cochrane-handbook.org. 2011 (21 March 2012, date last accessed)
33. Haring CM, Rietveld A, van den Brand JAJG et al. Segmental and global subclasses of class IV lupus nephritis have similar renal outcomes. J Am Soc Nephrol 2012; 23: 149-154
34. U.S. Renal Data System. USRDS 2011 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2011
35. Winkelmayer WC, Waikar SS, Mogun H et al. Nonselective and cyclooxygenase-2-selective NSAIDs and acute kidney injury. Am J Med 2008; 121: 1092-1098
36. Hung AM, Roumie CL, Greevy RA et al. Comparative effectiveness of incident oral antidiabetic drugs on kidney function. Kidney Int 2012; 81: 698-706
37. Port FK, Ashby VB, Dhingra RK et al. Dialysis dose and body mass index are strongly associated with survival in hemodialysis patients. J Am Soc Nephrol 2002; 13: 1061-1066
38. Held PJ, Port FK, Wolfe RA et al. The dose of hemodialysis and patient mortality. Kidney Int 1996; 50: 550-556
39. Eknoyan G, Beck GJ, Cheung AK et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002; 347: 2010-2019
40. Greene T, Daugirdas J, Depner T et al. Association of achieved dialysis dose with mortality in the hemodialysis study: an example of "dose-targeting bias". J Am Soc Nephrol 2005; 16: 3371-3380
41. Ioannidis JPA, Haidich A-B, Pappa M et al. Comparison of evidence of treatment effects in randomized and nonrandomized studies. JAMA 2001; 286: 821-830
42. Bradbury BD, Gilbertson DT, Brookhart MA et al. Confounding and control of confounding in nonexperimental studies of medications in patients with CKD. Adv Chronic Kidney Dis 2012; 19: 19-26
43. Ray WA. Evaluating medication effects outside of clinical trials: newuser designs. Am J Epidemiol 2003; 158: 915-920
44. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998; 17: 2265-2281
45. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983; 70: 41-55
46. Schneeweiss S, Rassen JA, Glynn RJ et al. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology 2009; 20: 512-522
47. Brookhart MA, Rassen JA, Schneeweiss S. Instrumental variable methods in comparative safety and effectiveness research. Pharmacoepidemiol Drug Saf 2010; 19: 537-554
48. Ramirez SPB, Albert JM, Blayney MJ et al. Rosiglitazone is associated with mortality in chronic hemodialysis patients. J Am Soc Nephrol 2009; 20: 1094-1101
49. McClellan M, McNeil BJ, Newhouse JP. Does more intensive treatment of acute myocardial infarction in the elderly reduce mortality? Analysis using instrumental variables. JAMA 1994; 272: 859-866
50. Bond TC, Nissenson AR, Krishnan M et al. Dialyzer reuse with peracetic acid does not impact patient mortality. C J Am Soc Nephrol 2011; 6: 1368-1374
51. Robins JM, Hernan MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology 2000; 11: 550-560
52. Deeks JJ, Dinnes J, D'Amico R et al. Evaluating non-randomised intervention studies. Health Technol Assess 2003; 7:iii-x, 1-173
53. Go AS, Chertow GM, Fan D et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305
54. Tonelli M, Wiebe N, Culleton B et al. Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol 2006; 17: 2034-2047
55. Strippoli GFM, Craig JC, Schena FP. The number, quality, and coverage of randomized controlled trials in nephrology. J Am Soc Nephrol 2004; 15: 411-419